

# Q2 2022

## INTERIM REPORT

**SEK 233.1** million

The Group's net sales increased to SEK 233.1 (181.0) million in the second quarter of 2022

**SEK 37.8** million

The Group's operating profit increased to SEK 37.8 (26.5) million in the second quarter of 2022



# Q2 2022 INTERIM REPORT

## April – June 2022

- Net sales for the second quarter amounted to SEK 233.1 (181.0) million, an increase of 28.8 percent compared to the same quarter last year. Net sales in local currencies increased by 19.7 percent.
- Operating profit amounted to SEK 37.8 (26.5) million, corresponding to an operating margin of 16.2 (14.7) percent.
- Profit after net financial items amounted to SEK 38.8 (22.8) million. Net financial items were positively affected by exchange rate differences of SEK 3.6 (-0.9) million and totaled SEK 1.1 (-3.7) million.
- Profit after tax amounted to SEK 29.7 (18.4) million.
- Cash flow from operating activities was SEK 26.4 (34.3) million, and SEK -3.8 (24.0) million after investments.
- Earnings per share amounted to SEK 3.68 (2.28).

## January – June 2022

- Net sales for the first half of the year amounted to SEK 427.6 (352.2) million, an increase of 21.4 percent compared to the same period last year. Net sales in local currencies increased by 13.9 percent.
- Operating profit amounted to SEK 67.0 (51.6) million, corresponding to an operating margin of 15.7 (14.7) percent.
- Profit after net financial items amounted to SEK 68.6 (50.0) million. Net financial items were positively affected by exchange rate differences of SEK 4.4 (1.9) million and totaled SEK 1.6 (-1.6) million.
- Profit after tax amounted to SEK 52.7 (38.4) million.
- Cash flow from operating activities was SEK 34.7 (58.7) million, and SEK -23.8 (12.6) million after investments.
- Earnings per share amounted to SEK 6.53 (4.76).

Key performance indicators	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021	Jul-Jun 2021/22	Jan-Dec 2021
Net sales, SEK million	233.1	181.0	427.6	352.2	799.0	723.6
Growth, %	28.8	53.0	21.4	27.1	22.0	24.8
Operating profit before depreciation and amortization (EBITDA), SEK million	53.7	39.7	98.4	78.1	177.0	156.6
Operating profit before depreciation and amortization (EBITDA), %	23.0	21.9	23.0	22.2	22.1	21.6
Operating profit (EBIT), SEK million	37.8	26.5	67.0	51.6	116.6	101.1
Operating profit (EBIT), %	16.2	14.7	15.7	14.7	14.6	14.0
Profit after financial items, SEK million	38.8	22.8	68.6	50.0	116.7	98.0
Undiluted and diluted earnings per share, SEK	3.68	2.28	6.53	4.76	11.14	9.37
Cash flow from operating activities, SEK million	26.4	34.3	34.7	58.7	81.0	105.0
Net debt, SEK million			302.0	250.8		261.3

# THE GROUP'S PERFORMANCE

## Net sales April-June 2022

The Group's net sales for the quarter increased to SEK 233.1 (181.0) million. The increase of 28.8 percent compared with the second quarter of last year is attributable to all business areas: Dental 12.5 percent, Orthopedics 45.0 percent and Life Science 32.6 percent. Sales of proprietary products in Dental business area grew 38.6 percent and accounted for 15.6 (14.5) percent of total consolidated net sales. Net sales in local currencies increased by 19.7 percent.

## Net sales January-June 2022

The Group's net sales for the first half year increased to SEK 427.6 (352.2) million. The increase of 21.4 percent compared with the same period last year is attributable to all business areas: Dental 16.5 percent, Orthopedics 26.1 percent and Life Science 22.3 percent. Sales of proprietary products in Dental business area grew 45.7 percent and accounted for 17.2 (14.3) percent of total consolidated net sales. Net sales in local currencies increased by 13.9 percent.

## Earnings April-June 2022

The operating profit for the second quarter amounted to SEK 37.8 (26.5) million, corresponding to an operating margin of 16.2 (14.7) percent. The Group's net financial items were positively affected by exchange rate differences of SEK 3.6 (-0.9) million and a revaluation of interest rate swap, which had a positive impact of SEK 1.5 (-0.4) million. Net financial items amounted to SEK 1.1 (-3.7) million. Earnings after financial items amounted to SEK 38.8 (22.8) million and earnings after tax amounted to SEK 29.7 (18.4) million.

## Earnings per share April-June 2022

Second quarter earnings per share both before and after dilution were SEK 3.68 (2.28) per share.

## Earnings January-June 2022

The operating profit for the first half of the year amounted to SEK 67.0 (51.6) million, corresponding to an operating margin of 15.7 (14.7) percent. The Group's net financial items were positively affected by exchange rate differences of SEK 4.4 (1.9) million and a revaluation of interest rate swap, which had a positive impact of SEK 4.0 (1.7) million. Net financial items amounted to SEK 1.6 (-1.6) million. Earnings after financial items amounted to SEK 68.6 (50.0) million and earnings after tax amounted to SEK 52.7 (38.4) million.

## Earnings per share January-June 2022

First half of the year earnings per share both before and after dilution were SEK 6.53 (4.76) per share.

## Investments

The Group's investments in the second quarter amounted to SEK 30.2 (10.3) million and mainly relate to investments in machinery for several of the Group's sites. In total for the year investments of SEK 58.5 (46.2) million.

## Financial position and liquidity

Consolidated total assets increased during the period to SEK 1,371.8 (1,076.4) million. Equity increased by SEK 104.3 million over the period with translation of foreign subsidiaries accounting for SEK 30.5 million of the increase. Total equity amounted to SEK 738.8 (581.2) million. Equity per share, calculated on 8,068,000 shares, amounted to SEK 91.57 (72.00). At the end of the year, risk-bearing capital was SEK 775.3 (605.0) million, which corresponds to 56.5 (56.2) percent of total capital. The Group's equity ratio was 53.9 (54.0) percent.

## Cash flow

The Group's cash flow from operating activities for the quarter amounted to SEK 26.4 (34.3) million. Operating cash flow in the quarter amounted to SEK -3.8 (24.0) million.

The Group's cash flow from operating activities for the first half of the year amounted to SEK 34.7 (58.7) million. Operating cash flow in the period amounted to SEK -23.8 (12.6) million.

The Group's net debt increased during the period, to SEK 302.0 (250.8) million. The Group's cash and cash equivalents amounted to SEK 160.2 (94.1) million.

## Personnel

The average number of employees in the Group in the second quarter was 613 compared to 528 in the previous year, which is an increase of 16 percent.

The average number of employees in the Group in the first half of the year was 597 compared to 530 from the previous year, which is an increase of 13 percent.

At the end of the period, the number of employees in the Group was 624 (520).

## Events during the quarter

During the quarter, the majority of the Group's existing bank loans were refinanced. The refinancing gives Elos Medtech increased borrowing possibilities for future growth.

## Events after the end of the quarter

No events after the balance sheet date have occurred that materially affect the assessment of the financial information contained in this report.

# OTHER INFORMATION

## Accounting policies

This interim report has been prepared in accordance with IAS 34 Interim Reporting and the relevant provisions of the Annual Accounts Act. The interim report of the Parent Company has been prepared in accordance with Chapter 9 of the Annual Accounts Act, Interim Report. For the Group and the Parent Company, the same accounting principles and calculation bases have been applied as in the most recent annual report.

In addition to the financial statements, disclosures in accordance with IAS 34.16A are also presented in parts of the interim report.

## Segment reporting

The internal financial follow-up per business area is adapted to the Group's various customer segments and uses operating profit as a measure to assess segment performance. Directly attributable items and items that can reasonably be allocated by segment have been included in the segment's operating profit.

Unallocated Group expenses refer mainly to note-related costs.

## Financial instruments at fair value

For the property loans in the US, the Group swaps its variable interest rate for a fixed rate through interest rate swaps. These interest rate swaps are recognized at fair value via the income statement. Unrealized gains and losses arising from fluctuations in the fair values of the financial instruments are recognized in net financial items in the consolidated income statement. For interest rate swaps, fair value is determined based on market prices. If such prices are not available, fair value is determined by discounting the difference between the contractual interest rate and the interest rate that can be obtained at the balance sheet date for the remaining contract term. Any premiums paid for the swap contract are recognized as interest over the term of the contract. As Elos Medtech intends to hold these derivatives to maturity, mark-to-market accounting of the derivatives over time will not affect earnings or cash flow.

Fair value measurement of interest rate derivatives had a positive impact on quarterly earnings of SEK 1.5 (-0.4) million, and a positive impact of SEK 4.0 (1.7) million on earnings for the first half year.

## Significant risks and uncertainties

The Group's principal risks and uncertainties include operational and financial risks. Among operational risks, Elos Medtech is primarily affected by risks associated with customers and markets, but also other external factors such as price risks for materials and supplies. The Group also faces financial risks associated with changes in exchange rates and credit risks. A detailed description of the Group's risks and uncertainties, as well as how these are being managed, is provided in the Directors' Report and in Notes 42 and 44 in the 2021 Annual Report.

Uncertainty in the geopolitical and security-related environment remains high but has not yet had a significant impact on the financial reporting. However, it cannot be ruled out that this will have an effect in the future. Elos Medtech continues to focus on customer deliveries by working actively with the Group's suppliers and secure good raw material levels.

## Related party transactions

The company had no transactions with related parties during the reporting period.

## Parent Company

In addition to the administration of central management issues, the parent company also provide Group-wide support in IT and marketing, quality management, risk management, financing, and financial control.

The Parent Company's net sales in the second quarter amounted to SEK 7.3 (6.5) million. Profit after financial items amounted to SEK 32.1 (9.4) million, of which SEK 20.2 (-3.9) million refers to exchange rate differences mainly related to the translation of loans to subsidiaries. The result was negatively affected by SEK 2.2 million due to changed basis of calculation for the PRI pension liability. SEK 1.4 million of this change has been reported as increased financial expenses. The Parent Company reported a profit after tax of SEK 29.2 (11.3) million. The percentage of risk-bearing capital was 55.7 (82.1) percent. The equity ratio was 55.5 (81.7) percent.

### Future-oriented information

The company does not make forecasts.

Future-oriented information in this report is based on management's expectations at the time of the report. Although the Board of Directors and management feel that these expectations are reasonable, it is no guarantee that the expectations are, or will prove to be, correct. Consequently, future outcomes may vary significantly compared to the future-oriented information due to such things as changes in the market conditions for the Group's services or changes in the overall situation concerning the economy, market and competition, changes in legal requirements and other policy measures as well as fluctuations in exchange rates. The company does not undertake to update or correct any future-oriented information except as stipulated by law.

### Examination by the auditors

This report has not been subject to a review by the company's auditors.

The Board of Directors and CEO certify that this half-yearly report provides a true and fair view of the company's and the Group's operations, financial position and performance and describes the significant risks and uncertainties faced by the company and companies belonging to the Group.

Gothenburg, August 18, 2022

Elos Medtech AB (publ)

Stefano Alfonsi  
*Chairman of the Board*

Birker Bahnsen  
*Board Member*

Lovisa Lander  
*Board Member*

Alexander Cicetti  
*Board Member*

Magnus René  
*Board Member*

Jodie Gilmore  
*CEO*

# CONDENSED CONSOLIDATED INCOME STATEMENT AND STATEMENT OF COMPREHENSIVE INCOME

SEK million		Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021	Jul-Jun 2021/22	Jan-Dec 2021
<b>Income statement</b>							
Net sales		233.1	181.0	427.6	352.2	799.0	723.6
Cost of goods sold		-147.2	-115.6	-268.1	-227.6	-508.6	-468.1
<b>Gross profit</b>		<b>85.9</b>	<b>65.4</b>	<b>159.5</b>	<b>124.6</b>	<b>290.4</b>	<b>255.5</b>
Selling expenses		-12.5	-9.6	-23.7	-17.8	-41.5	-35.6
Administrative expenses		-30.6	-25.4	-57.9	-46.5	-114.5	-103.1
Development costs		-6.5	-4.2	-12.5	-8.6	-21.6	-17.7
Other operating income/expenses		1.5	0.3	1.7	-0.1	3.8	2.0
<b>Operating profit</b>		<b>37.8</b>	<b>26.5</b>	<b>67.0</b>	<b>51.6</b>	<b>116.6</b>	<b>101.1</b>
Financial income		5.3	0.0	8.9	3.9	12.8	7.8
Financial expenses		-4.2	-3.7	-7.3	-5.5	-12.7	-10.9
<b>Profit after financial items</b>		<b>38.8</b>	<b>22.8</b>	<b>68.6</b>	<b>50.0</b>	<b>116.7</b>	<b>98.0</b>
Tax expense		-9.1	-4.4	-15.9	-11.6	-26.7	-22.4
<b>Profit after tax</b>		<b>29.7</b>	<b>18.4</b>	<b>52.7</b>	<b>38.4</b>	<b>90.0</b>	<b>75.6</b>
Attributable to Parent Company shareholders		29.7	18.4	52.7	38.4	90.0	75.6
Undiluted and diluted earnings per share, SEK*		3.68	2.28	6.53	4.76	11.14	9.37
* Attributable to Parent Company shareholders' share of profit after tax.							
<b>Statement of comprehensive income</b>							
<b>Profit after tax</b>		<b>29.7</b>	<b>18.4</b>	<b>52.7</b>	<b>38.4</b>	<b>90.0</b>	<b>75.6</b>
<b>Other comprehensive income</b>							
<b>Items that will not be reclassified to profit or loss</b>							
Actuarial gains and losses		2.8	2.9	6.4	2.9	-	-3.5
Tax		-0.6	-0.6	-1.3	-0.6	-	0.7
		2.3	2.3	5.1	2.3	-	-2.8
<b>Items that may be reclassified to profit or loss</b>							
Translation differences for the period		40.0	-8.4	50.7	13.2	73.9	36.4
Tax		-3.4	0.7	-4.2	-1.0	-5.9	-2.7
		36.6	-7.7	46.5	12.2	68.0	33.7
<b>Other comprehensive income. net</b>		<b>38.8</b>	<b>-5.5</b>	<b>51.6</b>	<b>14.5</b>	<b>68.0</b>	<b>30.9</b>
<b>Comprehensive income for the year</b>		<b>68.5</b>	<b>12.9</b>	<b>104.3</b>	<b>52.9</b>	<b>158.0</b>	<b>106.5</b>
Parent Company shareholders		68.5	12.9	104.3	52.9	158.0	106.5
Operating profit before depreciation and amortization (EBITDA)	%	23.0	21.9	23.0	22.2	22.1	21.6
Operating profit (EBIT)	%	16.2	14.7	15.7	14.7	14.6	14.0
Depreciation and amortization charged to earnings	SEK million	16.0	13.2	31.4	26.5	60.4	55.5

# CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

SEK million

Balance sheet	30 Jun 2022	30 Jun 2021	31 Dec 2021
<b>Assets</b>			
Intangible assets	302.1	260.3	272.3
Property, plant and equipment	529.5	442.1	469.5
Financial fixed assets	0.5	1.5	1.4
Current assets	379.6	278.3	288.1
Cash and cash equivalents	160.2	94.1	95.1
<b>Total assets</b>	<b>1 371.8</b>	<b>1 076.4</b>	<b>1 126.4</b>
<b>Equity and liabilities</b>			
Equity	738.8	581.2	634.4
Non-current liabilities	474.4	316.5	316.6
Current liabilities	158.6	178.6	175.4
<b>Total equity and liabilities</b>	<b>1 371.8</b>	<b>1 076.4</b>	<b>1 126.4</b>

# CONDENSED CONSOLIDATED CASH FLOWS STATEMENT

SEK million	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021	Jul-Jun 2021/22	Jan-Dec 2021
<b>Cash flow</b>						
Profit after net financial items	38.8	22.8	68.6	50.0	116.6	98.0
Reversal of depreciation and amortization	16.0	13.2	31.4	26.5	60.4	55.5
Adjustment for non-cash items	-3.7	1.4	-7.5	-1.2	-8.4	-2.1
Tax paid	-3.4	-2.5	-6.4	-5.7	-18.9	-18.2
Changes in working capital	-21.2	-0.6	-51.3	-10.9	-68.6	-28.2
<b>Cash flow from operating activities</b>	<b>26.4</b>	<b>34.3</b>	<b>34.7</b>	<b>58.7</b>	<b>81.0</b>	<b>105.0</b>
Investments in fixed assets	-30.2	-10.3	-58.5	-46.2	-97.8	-85.5
Sale of fixed assets	-	-	-	0.1	-	0.1
<b>Cash flow from investing activities</b>	<b>-30.2</b>	<b>-10.3</b>	<b>-58.5</b>	<b>-46.1</b>	<b>-97.8</b>	<b>-85.4</b>
<b>Operating cash flow</b>	<b>-3.8</b>	<b>24.0</b>	<b>-23.8</b>	<b>12.6</b>	<b>-16.8</b>	<b>19.6</b>
Borrowings	302.3	21.1	339.8	30.2	370.5	60.9
Repayment of borrowings	-230.9	-14.9	-258.7	-27.7	-298.8	-67.8
Dividend to shareholders	-	-12.1	-	-12.1	-	-12.1
<b>Cash flow from financing activities</b>	<b>71.5</b>	<b>-5.9</b>	<b>81.2</b>	<b>-9.6</b>	<b>71.8</b>	<b>-19.0</b>
<b>Cash flow for the period</b>	<b>67.6</b>	<b>18.1</b>	<b>57.4</b>	<b>3.0</b>	<b>55.0</b>	<b>0.5</b>
Cash and cash equivalents at the beginning of the period	86.8	76.7	95.1	88.5	94.1	88.5
Exchange rate difference in cash and cash equivalents	5.6	-0.7	7.6	2.7	11.0	6.1
<b>Cash and cash equivalents at the end of the period</b>	<b>160.1</b>	<b>94.1</b>	<b>160.1</b>	<b>94.1</b>	<b>160.1</b>	<b>95.1</b>

# CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

SEK million	30 Jun 2022	30 Jun 2021	31 Dec 2021
Opening balance	634.4	540.3	540.3
Total comprehensive income	104.3	52.9	106.2
Dividend	-	-12.1	-12.1
<b>Closing equity</b>	<b>738.8</b>	<b>581.2</b>	<b>634.4</b>

## KEY PERFORMANCE INDICATORS, GROUP

		Jan-Jun 2022	Jan-Jun 2021	Jan-Dec 2021
Return on operating capital	%	13.1	10.5	12.0
Return on equity*	%	13.6	11.0	12.9
Share of risk-bearing capital	%	56.5	56.2	58.9
Equity ratio	%	53.9	54.0	56.3
Net debt/EBITDA*	times	1.7	1.7	1.7
Investments, not including acquisitions	SEK million	58.5	10.3	85.5
Average number of employees	number	597	530	535

\*R12

## DATA PER SHARE

		Jan-Jun 2022	Jan-Jun 2021	Jan-Dec 2021
Undiluted and diluted earnings per share, SEK*	SEK million	6.53	4.76	9.37
Average number of shares	thousands	8,068.0	8,068.0	8,068.0
Number of shares at the end of the period	thousands	8,068.0	8,068.0	8,068.0
Equity per share	SEK	91.6	72.0	78.6
Share price at the end of the period	SEK	250.0	215.0	274.0
Dividend	SEK	-	-	-

\* Attributable to Parent Company shareholders' share of profit after tax



# BUSINESS AREA INFORMATION

SEK million			Growth			Growth		
Net sales by business area	Apr-Jun 2022	Apr-Jun 2021	Apr-Jun 2022	Jan-Jun 2022	Jan-Jun 2021	Jan-Jun 2022	Jul/Jun 2021/22	Jan-dec 2021
Dental	80.4	71.5	12.5%	157.6	135.2	16.5%	298.2	275.8
Orthopedics	87.5	60.4	45.0%	150.2	119.1	26.1%	267.5	236.3
Life Science	65.1	49.1	32.6%	119.7	97.9	22.3%	233.3	211.4
<b>Total net sales</b>	<b>233.1</b>	<b>181.0</b>	<b>28.8%</b>	<b>427.6</b>	<b>352.2</b>	<b>21.4%</b>	<b>799.0</b>	<b>723.6</b>

The value of sales between business areas is minor.

SEK million							
EBITDA by business area	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021	Jul/Jun 2021/22	Jan-Dec 2021	
Dental	20.4	17.3	43.7	33.6	77.9	67.8	
Orthopedics	16.0	15.8	22.9	26.5	49.6	53.2	
Life Science	18.3	11.6	34.0	24.3	66.4	56.7	
Unallocated Group expenses	-1.1	-5.0	-2.4	-6.2	-17.5	-21.3	
<b>Total profit before depreciation and amortization</b>	<b>53.7</b>	<b>39.7</b>	<b>98.4</b>	<b>78.1</b>	<b>177.0</b>	<b>156.6</b>	
<b>Depreciation and amortization by business area</b>							
Dental	-4.8	-4.5	-9.7	-9.1	-18.2	-17.6	
Orthopedics	-6.4	-4.4	-12.2	-9.0	-22.3	-19.1	
Life Science	-4.6	-4.3	-9.4	-8.5	-19.4	-18.5	
<b>Total depreciation and amortization</b>	<b>-16.0</b>	<b>-13.2</b>	<b>-31.4</b>	<b>-26.5</b>	<b>-60.4</b>	<b>-55.5</b>	
<b>Operating profit by business area</b>							
Dental	15.6	12.8	34.0	24.5	59.7	50.2	
Orthopedics	9.6	11.4	10.7	17.5	27.3	34.1	
Life Science	13.7	7.3	24.6	15.8	47.0	38.2	
Unallocated Group expenses	-1.1	-5.0	-2.4	-6.2	-17.5	-21.3	
<b>Total operating profit</b>	<b>37.8</b>	<b>26.5</b>	<b>67.0</b>	<b>51.6</b>	<b>116.6</b>	<b>101.1</b>	

# QUARTERLY RESULTS FOR THE GROUP

SEK million	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020
Quarterly results								
<b>Net sales</b>	<b>233.1</b>	<b>194.5</b>	<b>184.2</b>	<b>187.2</b>	<b>181.0</b>	<b>171.2</b>	<b>154.8</b>	<b>147.9</b>
Cost of goods sold	-147.2	-120.9	-121.4	-119.1	-115.6	-112.0	-102.6	-100.4
<b>Gross profit</b>	<b>85.9</b>	<b>73.5</b>	<b>62.8</b>	<b>68.1</b>	<b>65.4</b>	<b>59.2</b>	<b>52.2</b>	<b>47.5</b>
Sales, admin and development costs	-49.6	-44.4	-39.9	-43.6	-39.2	-33.8	-32.2	-30.3
Other operating income and expenses	1.5	0.2	2.4	-0.3	0.3	-0.4	-1.1	0.7
<b>Operating profit</b>	<b>37.8</b>	<b>29.2</b>	<b>25.3</b>	<b>24.2</b>	<b>26.5</b>	<b>25.0</b>	<b>18.9</b>	<b>17.9</b>
Financial income	5.3	3.6	2.2	1.8	-	4.9	-	-
Financial expenses	-4.2	-3.0	-2.7	-2.7	-3.7	-2.8	-5.6	-3.7
<b>Profit after financial items</b>	<b>38.8</b>	<b>29.8</b>	<b>24.8</b>	<b>23.3</b>	<b>22.8</b>	<b>27.1</b>	<b>13.3</b>	<b>14.2</b>
Tax expense	-9.1	-6.8	-5.2	-5.7	-4.4	-7.1	-2.2	-1.6
<b>Profit after tax</b>	<b>29.7</b>	<b>23.0</b>	<b>19.5</b>	<b>17.6</b>	<b>18.4</b>	<b>20.0</b>	<b>11.1</b>	<b>12.6</b>

# PARENT COMPANY INCOME STATEMENT

SEK million	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jul-Jun	Jan-Dec
Income statement	2022	2021	2022	2021	2021/22	2021
<b>Net sales</b>	<b>7.3</b>	<b>6.5</b>	<b>14.5</b>	<b>13.0</b>	<b>25.8</b>	<b>24.3</b>
Selling expenses	-2.6	-2.2	-4.2	-4.4	-7.8	-8.0
Administrative expenses	-12.8	-10.8	-21.1	-17.5	-50.2	-46.6
Other operating income/expenses	0.1	-	0.1	-0.1	0.1	-0.1
<b>Operating profit</b>	<b>-8.0</b>	<b>-6.5</b>	<b>-10.7</b>	<b>-9.0</b>	<b>-32.1</b>	<b>-30.4</b>
Income from investments in Group companies	19.4	19.0	19.4	19.0	44.4	44.0
Interest income, Group companies	2.9	1.1	4.1	2.2	6.4	4.5
Other interest income and similar income	20.7	-	24.7	6.0	34.9	16.2
Other interest expense and similar charges	-2.9	-4.2	-4.7	-0.9	-5.2	-1.4
<b>Profit after financial items</b>	<b>32.1</b>	<b>9.4</b>	<b>32.8</b>	<b>17.3</b>	<b>48.4</b>	<b>32.9</b>
Appropriations	-	-	-	-	-2.8	-2.8
Tax on profit for the year	-2.9	1.9	-3.1	0.2	-5.8	-2.5
<b>Profit after tax</b>	<b>29.2</b>	<b>11.3</b>	<b>29.7</b>	<b>17.5</b>	<b>39.8</b>	<b>27.6</b>

\* Profit after tax is the same as comprehensive income for the year.

# CONDENSED PARENT COMPANY BALANCE SHEET

SEK million	30 Jun 2022	30 Jun 2021	31 Dec 2021
Balance sheet			
<b>Assets</b>			
Intangible assets	2.9	4.0	3.3
Property, plant and equipment	0.2	0.3	0.2
Financial fixed assets	668.3	403.6	412.8
Current assets	46.6	35.9	62.5
Cash and cash equivalents	67.7	38.1	26.9
<b>Total assets</b>	<b>785.7</b>	<b>481.9</b>	<b>505.7</b>
<b>Equity and liabilities</b>			
Equity	430.2	390.4	400.5
Untaxed reserves	7.0	4.1	7.0
Provisions for pensions	10.2	7.9	8.5
Non-current liabilities	306.9	21.5	17.2
Current liabilities	31.4	58.0	72.5
<b>Total equity and liabilities</b>	<b>785.7</b>	<b>481.9</b>	<b>505.7</b>

# RECONCILIATION BASIS FOR ALTERNATIVE PERFORMANCE MEASURE

The interim report presents certain financial performance measures of earnings trend, financial position and cash flow that are not defined in accordance with IFRS. These performance measures are intended to serve as important supplementary performance indicators of the Group's performance and financial position and the purpose is to provide a better understanding of the business. Elos Medtech's definitions of these measures may differ from other companies' definitions of the same concepts. The alternative performance measures presented in the interim reports should not be regarded as a replacement to terms and concepts in accordance with IFRS. They are instead intended as a supplement.

Calculations of non-IFRS performance measures that are not mentioned elsewhere in the interim report are presented below. For complete information regarding the calculation and reasons for using alternative performance measures, please see: [www.elosmedtech.com](http://www.elosmedtech.com).

SEK million	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021	Jul-Jun 2021/22	Jan-Dec 2021
<b>Growth</b>						
Reported net sales	233.1	181.0	427.6	352.2	799.0	723.6
Net sales for the corresponding period last year	181.0	118.3	352.2	277.2	655.0	580.0
<b>Change in net sales</b>	<b>52.1</b>	<b>62.7</b>	<b>75.4</b>	<b>75.0</b>	<b>144.0</b>	<b>143.6</b>
<b>Growth, %</b>	<b>28.8</b>	<b>53.0</b>	<b>21.4</b>	<b>27.1</b>	<b>22.0</b>	<b>24.8</b>
<b>Net sales adjusted for exchange rate changes</b>						
Exchange rate changes	13.7	-7.2	23.2	-16.0	24.2	-15.0
Net sales for the corresponding period last year adjusted for exchange rate changes	194.7	111.1	375.4	261.2	679.2	565.0
<b>Growth adjusted for exchange rate changes, %</b>	<b>19.7</b>	<b>62.9</b>	<b>13.9</b>	<b>34.8</b>	<b>17.6</b>	<b>28.2</b>
<b>EBITDA</b>	<b>Apr-Jun 2022</b>	<b>Apr-Jun 2021</b>	<b>Jan-Jun 2022</b>	<b>Jan-Jun 2021</b>	<b>Jul-Jun 2021/22</b>	<b>Jan-Dec 2021</b>
Reported operating profit	37.8	26.5	67.0	51.6	116.6	101.1
Depreciation/amortization	16.0	13.2	31.4	26.5	60.4	55.5
<b>EBITDA</b>	<b>53.7</b>	<b>39.7</b>	<b>98.4</b>	<b>78.1</b>	<b>177.0</b>	<b>156.6</b>
<b>Risk-bearing capital</b>	<b>30 Jun 2022</b>	<b>30 Jun 2021</b>	<b>31 Dec 2021</b>			
Equity	738.8	581.2	634.4			
Deferred tax liability	36.5	23.8	28.9			
<b>Risk-bearing capital</b>	<b>775.3</b>	<b>605.0</b>	<b>663.3</b>			
<b>Net debt</b>	<b>30 Jun 2022</b>	<b>30 Jun 2021</b>	<b>31 Dec 2021</b>			
Non-current interest-bearing provisions for pensions	64.1	62.4	69.9			
Non-current interest-bearing liabilities	373.9	230.3	217.2			
Current interest-bearing liabilities	24.3	52.2	69.3			
<b>Total liabilities</b>	<b>462.2</b>	<b>344.9</b>	<b>356.4</b>			
Cash and cash equivalents	-160.2	-94.1	-95.1			
<b>Net debt</b>	<b>302.0</b>	<b>250.8</b>	<b>261.3</b>			
<b>Liquidity reserve</b>	<b>30 Jun 2022</b>	<b>30 Jun 2021</b>	<b>31 Dec 2021</b>			
Cash and cash equivalents	160.2	94.1	95.1			
Bank overdraft facilities granted	-	67.2	67.5			
<b>Liquidity reserve</b>	<b>160.2</b>	<b>161.3</b>	<b>162.6</b>			

## Financial calendar

Activity	Date
Interim report January-September 2022	October 21, 2022
Year-end report 2022	February 23, 2023

## Publication

This information is information that Elos Medtech AB (publ) is required to publish under the EU Market Abuse Regulation. The information was submitted for publication by the above contact person on August 18 at 8:00 a.m. (CEST).

Elos Medtech AB (publ) is a Swedish limited liability company, whose B shares are listed on Mid Cap, NASDAQ Stockholm AB. Elos Medtech's corporate governance is based on Swedish legislation and the company's listing agreement with NASDAQ Stockholm AB.

This is a translation of the Swedish version of the Q2 Interim report 2022. When in doubt, the Swedish wording prevails.

.....

For questions about the report, please contact:




**Jodie Gilmore**  
CEO and President & Business Unit  
Director Orthopedics  
Tel: +1 (901) 830 4552  
Email: [jodie.gilmore@elosmedtech.com](mailto:jodie.gilmore@elosmedtech.com)



**Ewa Linsäter**  
Chief Financial Officer  
Tel: +46 76 633 32 33  
Email: [ewa.linsater@elosmedtech.com](mailto:ewa.linsater@elosmedtech.com)

# FIND US HERE



## Elos Medtech AB (publ)

Torsgatan 5B  
SE-411 04 Gothenburg  
Sweden  
Tel: +46 10 171 20 00  
Corp. ID no: 556021-9650  
[info@elosmedtech.com](mailto:info@elosmedtech.com)  
[www.elosmedtech.com](http://www.elosmedtech.com)

